KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Non-Current Assets: 2009-2024

Historic Other Non-Current Assets for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $1.8 billion.

  • Teva Pharmaceutical Industries' Other Non-Current Assets rose 294.12% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 294.12%. This contributed to the annual value of $1.8 billion for FY2024, which is 276.81% up from last year.
  • As of FY2024, Teva Pharmaceutical Industries' Other Non-Current Assets stood at $1.8 billion, which was up 276.81% from $470.0 million recorded in FY2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Other Non-Current Assets peaked at $1.8 billion during FY2024, and registered a low of $441.0 million during FY2022.
  • Moreover, its 3-year median value for Other Non-Current Assets was $470.0 million (2023), whereas its average is $894.0 million.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Other Non-Current Assets declined by 14.37% in 2022 and then skyrocketed by 276.81% in 2024.
  • Teva Pharmaceutical Industries' Other Non-Current Assets (Yearly) stood at $538.0 million in 2020, then dropped by 4.28% to $515.0 million in 2021, then fell by 14.37% to $441.0 million in 2022, then increased by 6.58% to $470.0 million in 2023, then soared by 276.81% to $1.8 billion in 2024.